LEIDEN, NETHERLANDS--(Marketwire - December 11, 2008) - Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL) (SWISS: CRX) today announced that its monoclonal antibody (mAb) directed against a broad range of influenza virus strains has strongly outperformed the most current anti-influenza drug in preclinical tests.
